Detailed functional characterization of glycosylated and nonglycosylated variants of malaria vaccine candidate PfAMA1 produced in Nicotiana benthamiana and analysis of growth inhibitory responses in rabbits

Plant Biotechnology Journal

Volumn 13, Issue 2, 2015, Pages 222-234

  Boes, Alexander ^a   Spiegel, Holger ^a   Edgue, Gueven ^a   Kapelski, Stephanie ^a   Scheuermayer, Matthias ^b   Fendel, Rolf ^a   Remarque, Edmond ^c   Altmann, Friedrich ^d   Maresch, Daniel ^d   Reimann, Andreas ^a   Pradel, Gabriele ^e   Schillberg, Stefan ^a   Fischer, Rainer ^a,e  

^a FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^d UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

^e RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Glycosylation; Malaria; Plants; Plasmodium falciparum; Transient expression; Vaccine

Indexed keywords

EUKARYOTA; NICOTIANA BENTHAMIANA; ORYCTOLAGUS CUNICULUS; PICHIA PASTORIS; PLASMODIUM FALCIPARUM;

ANTISERUM; APICAL MEMBRANE ANTIGEN I, PLASMODIUM; IMMUNOGLOBULIN G; MALARIA VACCINE; MEMBRANE PROTEIN; PARASITE ANTIGEN; POLYSACCHARIDE; PROTOZOAL PROTEIN;

ANIMAL; CHEMICAL STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; GLYCOSYLATION; GROWTH, DEVELOPMENT AND AGING; IMMUNIZATION; IMMUNOLOGY; MEROZOITE; METABOLISM; MOLECULAR CLONING; PARASITE; PICHIA; PLASMODIUM FALCIPARUM; POLYACRYLAMIDE GEL ELECTROPHORESIS; RABBIT; SURFACE PLASMON RESONANCE; TOBACCO; TRANSGENIC PLANT;

ANIMALS; ANTIGENS, PROTOZOAN; CLONING, MOLECULAR; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORESCENT ANTIBODY TECHNIQUE; GLYCOSYLATION; IMMUNE SERA; IMMUNIZATION; IMMUNOGLOBULIN G; MALARIA VACCINES; MEMBRANE PROTEINS; MEROZOITES; MODELS, MOLECULAR; PARASITES; PICHIA; PLANTS, GENETICALLY MODIFIED; PLASMODIUM FALCIPARUM; POLYSACCHARIDES; PROTOZOAN PROTEINS; RABBITS; SURFACE PLASMON RESONANCE; TOBACCO;

EID: 84922756512     PISSN: 14677644     EISSN: 14677652     Source Type: Journal    
DOI: 10.1111/pbi.12255     Document Type: Article

References (64)

1. Agnandji, S.T., Lell, B., Soulanoudjingar, S.S., Fernandes, J.F., Abossolo, B.P., Conzelmann, C., Methogo, B.G., Doucka, Y., Flamen, A., Mordmuller, B., Issifou, S., Kremsner, P.G., Sacarlal, J., Aide, P., Lanaspa, M., Aponte, J.J., Nhamuave, A., Quelhas, D., Bassat, Q., Mandjate, S., Macete, E., Alonso, P., Abdulla, S., Salim, N., Juma, O., Shomari, M., Shubis, K., Machera, F., Hamad, A.S., Minja, R., Mtoro, A., Sykes, A., Ahmed, S., Urassa, A.M., Ali, A.M., Mwangoka, G., Tanner, M., Tinto, H., D'Alessandro, U., Sorgho, H., Valea, I., Tahita, M.C., Kabore, W., Ouedraogo, S., Sandrine, Y., Guiguemde, R.T., Ouedraogo, J.B., Hamel, M.J., Kariuki, S., Odero, C., Oneko, M., Otieno, K., Awino, N., Omoto, J., Williamson, J., Muturi-Kioi, V., Laserson, K.F., Slutsker, L., Otieno, W., Otieno, L., Nekoye, O., Gondi, S., Otieno, A., Ogutu, B., Wasuna, R., Owira, V., Jones, D., Onyango, A.A., Njuguna, P., Chilengi, R., Akoo, P., Kerubo, C., Gitaka, J., Maingi, C., Lang, T., Olotu, A., Tsofa, B., Bejon, P., Peshu, N., Marsh, K., Owusu-Agyei, S., Asante, K.P., Osei-Kwakye, K., Boahen, O., Ayamba, S., Kayan, K., Owusu-Ofori, R., Dosoo, D., Asante, I., Adjei, G., Adjei, G., Chandramohan, D., Greenwood, B., Lusingu, J., Gesase, S., Malabeja, A., Abdul, O., Kilavo, H., Mahende, C., Liheluka, E., Lemnge, M., Theander, T., Drakeley, C., Ansong, D., Agbenyega, T., Adjei, S., Boateng, H.O., Rettig, T., Bawa, J., Sylverken, J., Sambian, D., Agyekum, A., Owusu, L., Martinson, F., Hoffman, I., Mvalo, T., Kamthunzi, P., Nkomo, R., Msika, A., Jumbe, A., Chome, N., Nyakuipa, D., Chintedza, J., Ballou, W.R., Bruls, M., Cohen, J., Guerra, Y., Jongert, E., Lapierre, D., Leach, A., Lievens, M., Ofori-Anyinam, O., Vekemans, J., Carter, T., Leboulleux, D., Loucq, C., Radford, A., Savarese, B., Schellenberg, D., Sillman, M., Vansadia, P., Rts, S.and Clinical Trials Partnership (2011) First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children. N. Engl. J. Med. 365, 1863-1875.
2. Anders, R.F., Crewther, P.E., Edwards, S., Margetts, M., Matthew, M.L., Pollock, B. and Pye, D. (1998) Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi. Vaccine, 16, 240-247.
3. Bardor, M., Faveeuw, C., Fitchette, A.-C., Gilbert, D., Galas, L., Trottein, F., Faye, L. and Lerouge, P. (2003) Immunoreactivity in mammals of two typical plant glyco-epitopes, core alpha(1, 3)-fucose and core xylose. Glycobiology, 13, 427-434.
4. Barr, P.J., Green, K.M., Gibson, H.L., Bathurst, I.C., Quakyi, I.A. and Kaslow, D.C. (1991) Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals. J. Exp. Med. 174, 1203-1208.
5. Boes, A., Spiegel, H., Delbrück, H., Fischer, R., Schillberg, S. and Sack, M. (2011) Affinity purification of a framework 1 engineered mouse/human chimeric IgA2 antibody from tobacco. Biotechnol. Bioeng. 108, 2804-2814.
6. Bradford, M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.
7. Bruder, J.T., Stefaniak, M.E., Patterson, N.B., Chen, P., Konovalova, S., Limbach, K., Campo, J.J., Ettyreddy, D., Li, S., Dubovsky, F., Richie, T.L., Richter King, C., Long, C.A. and Doolan, D. (2010) Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growth. Vaccine, 28, 3201-3210.
8. Clemente, M. and Corigliano, M.G. (2012) Overview of plant-made vaccine antigens against malaria. J. Biomed. Biotechnol. 2012, 206918.
9. Coley, A.M., Campanale, N.V., Casey, J.L., Hodder, A.N., Crewther, P.E., Anders, R.F., Tilley, L.M. and Foley, M. (2001) Rapid and precise epitope mapping of monoclonal antibodies against Plasmodium falciparum AMA1 by combined phage display of fragments and random peptides. Protein Eng. 14, 691-698.
10. Collins, W.E., Pye, D., Crewther, P.E., Vandenberg, K.L., Galland, G.G., Sulzer, A.J., Kemp, D.J., Edwards, S.J., Coppel, R.L. and Sullivan, J.S. (1994) Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 of Plasmodium fragile. Am. J. Trop. Med. Hyg. 51, 711-719.
11. Collins, C.R., Withers-Martinez, C., Bentley, G.A., Batchelor, A.H., Thomas, A.W. and Blackman, M.J. (2007) Fine mapping of an epitope recognized by an invasion-inhibitory monoclonal antibody on the malaria vaccine candidate apical membrane antigen 1. J. Biol. Chem. 282, 7431-7441.
12. Cortes, A., Mellombo, M., Masciantonio, R., Murphy, V.J., Reeder, J.C. and Anders, R.F. (2005) Allele specificity of naturally acquired antibody responses against Plasmodium falciparum apical membrane antigen 1. Infect. Immun. 73, 422-430.
13. Deans, J.A., Knight, A.M., Jean, W.C., Waters, A.P., Cohen, S. and Mitchell, G.H. (1988) Vaccination trials in rhesus monkeys with a minor, invariant, Plasmodium knowlesi 66 kD merozoite antigen. Parasite Immunol. 10, 535-552.
14. Dutta, S., Lalitha, P.V., Ware, L.A., Barbosa, A., Moch, J.K., Vassell, M.A., Fileta, B.B., Kitov, S., Kolodny, N., Heppner, D.G., Haynes, J.D. and Lanar, D.E. (2002) Purification, characterization, and immunogenicity of the refolded ectodomain of the Plasmodium falciparum apical membrane antigen 1 expressed in Escherichia coli. Infect. Immun. 70, 3101-3110.
15. Faber, B.W., Remarque, E.J., Kocken, C.H., Cheront, P., Cingolani, D., Xhonneux, F., Jurado, M., Haumont, M., Jepsen, S., Leroy, O. and Thomas, A.W. (2008) Production, quality control, stability and pharmacotoxicity of cGMP-produced Plasmodium falciparum AMA1 FVO strain ectodomain expressed in Pichia pastoris. Vaccine, 26, 6143-6150.
16. Farrance, C.E., Chichester, J.A., Musiychuk, K., Shamloul, M., Rhee, A., Manceva, S.D., Jones, R.M., Mamedov, T., Sharma, S., Mett, V., Streatfield, S., Roeffen, W., van de Vegte-Bolmer, M., Sauerwein, R., Wu, Y., Muratova, O., Miller, L., Duffy, P., Sinden, R. and Yusibov, V. (2011a) Antibodies to plant-produced Plasmodium falciparum sexual stage protein Pfs25 exhibit transmission blocking activity. Hum. Vaccin. 7, 191-198.
17. Farrance, C.E., Rhee, A., Jones, R.M., Musiychuk, K., Shamloul, M., Sharma, S., Mett, V., Chichester, J.A., Streatfield, S.J., van de Roeffen, W., Vegte-Bolmer, M., Sauerwein, R.W., Tsuboi, T., Muratova, O.V., Wu, Y. and Yusibov, V. (2011b) A Plant-Produced Pfs230 Vaccine Candidate Blocks Transmission of Plasmodium falciparum. Clin. Vaccine Immunol. 18, 1351-1357.
18. Feller, T., Thom, P., Koch, N., Spiegel, H., Addai-Mensah, O., Fischer, R., Reimann, A., Pradel, G., Fendel, R., Schillberg, S., Scheuermayer, M. and Schinkel, H. (2013) Plant-based production of recombinant Plasmodium surface protein Pf38 and evaluation of its potential as a vaccine candidate. PLoS ONE, 8, e79920-e79920.
19. Fischer, R., Schillberg, S., Buyel, J.F. and Twyman, R.M. (2013) Commercial aspects of pharmaceutical protein production in plants. Curr. Pharm. Des. 19, 5471-5477.
20. Garrity, R.R., Rimmelzwaan, G., Minassian, A., Tsai, W.P., Lin, G., de Jong, J.J., Goudsmit, J. and Nara, P.L. (1997) Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope. J. Immunol. 159, 279-289.
21. Giersing, B., Miura, K., Shimp, R., Wang, J., Zhou, H., Orcutt, A., Stowers, A., Saul, A., Miller, L.H., Long, C.A. and Singh, S. (2005) Posttranslational modification of recombinant Plasmodium falciparum apical membrane antigen 1: impact on functional immune responses to a malaria vaccine candidate. Infect. Immun. 73, 3963-3970.
22. Hamorsky, K.T., Kouokam, J.C., Bennett, L.J., Baldauf, K.J., Kajiura, H., Fujiyama, K. and Matoba, N. (2013) Rapid and scalable plant-based production of a cholera toxin B subunit variant to aid in mass vaccination against cholera outbreaks. PLoS Negl. Trop. Dis. 7, e2046.
23. Hoffman, S.L., Nussenzweig, V., Sadoff, J.C. and Nussenzweig, R.S. (1991) Progress toward malaria preerythrocytic vaccines. Science, 252, 520-521.
24. Ifediba, T. and Vanderberg, J.P. (1981) Complete in vitro maturation of Plasmodium falciparum gametocytes. Nature, 294, 364-366.
25. Igonet, S., Vulliez-Le Normand, B., Faure, G., Riottot, M.M., Kocken, C.H., Thomas, A.W. and Bentley, G.A. (2007) Cross-reactivity studies of an anti-Plasmodium vivax apical membrane antigen 1 monoclonal antibody: binding and structural characterisation. J. Mol. Biol., 366, 1523-1537.
26. von Itzstein, M., Plebanski, M., Cooke, B.M. and Coppel, R.L. (2008) Hot, sweet and sticky: the glycobiology of Plasmodium falciparum. Trends Parasitol. 24, 210-218.
27. Kedees, M.H., Azzouz, N., Gerold, P., Shams-Eldin, H., Iqbal, J., Eckert, V. and Schwarz, R.T. (2002) Plasmodium falciparum: glycosylation status of Plasmodium falciparum circumsporozoite protein expressed in the baculovirus system. Exp. Parasitol. 101, 64-68.
28. Kennedy, M.C., Wang, J., Zhang, Y., Miles, A.P., Chitsaz, F., Saul, A., Long, C.A., Miller, L.H. and Stowers, A.W. (2002) In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect. Immun. 70, 6948-6960.
29. Kocken, C.H., van der Wel, A.M., Dubbeld, M.A., Narum, D.L., van de Rijke, F.M., Van Gemert, G.J., van der Linde, X., Bannister, L.H., Janse, C., Waters, A.P. and Thomas, A.W. (1998) Precise timing of expression of a Plasmodium falciparum-derived transgene in Plasmodium berghei is a critical determinant of subsequent subcellular localization. J. Biol. Chem. 273, 15119-15124.
30. Kocken, C.H., Withers-Martinez, C., Dubbeld, M.A., van der Wel, A., Hackett, F., Blackman, M.J. and Thomas, A.W. (2002) High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion. Infect. Immun. 70, 4471-4476.
31. Koncz, C. and Schell, J. (1986) The promoter of Tl-DNA gene 5 controls the tissue-specific expression of chimeric genes carried by a novel type of agrobacterium binary vector. Mol. Genet. Genomics 204, 383-396.
32. Lambros, C. and Vanderberg, J.P. (1979) Synchronization of Plasmodium falciparum erythrocytic stages in culture. J. Parasitol. 65, 418-420.
33. Maclean, J., Koekemoer, M., Olivier, A.J., Stewart, D., Hitzeroth, I.I., Rademacher, T., Fischer, R., Williamson, A.L. and Rybicki, E.P. (2007) Optimization of human papillomavirus type 16 (HPV-16) L1 expression in plants: comparison of the suitability of different HPV-16 L1 gene variants and different cell-compartment localization. J. Gen. Virol. 88, 1460-1469.
34. Mir-Shekari, S.Y., Ashford, D.A., Harvey, D.J., Dwek, R.A. and Schulze, I.T. (1997) The glycosylation of the influenza A virus hemagglutinin by mammalian cells. A site-specific study. J. Biol. Chem. 272, 4027-4036.
35. Miura, K., Zhou, H., Diouf, A., Moretz, S.E., Fay, M.P., Miller, L.H., Martin, L.B., Pierce, M.A., Ellis, R.D., Mullen, G.E. and Long, C.A. (2009) Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay. Clin. Vaccine Immunol. 16, 963-968.
36. Narum, D.L. and Thomas, A.W. (1994) Differential localization of full-length and processed forms of PF83/AMA-1 an apical membrane antigen of Plasmodium falciparum merozoites. Mol. Biochem. Parasitol. 67, 59-68.
37. Narum, D.L., Ogun, S.A., Thomas, A.W. and Holder, A.A. (2000) Immunization with parasite-derived apical membrane antigen 1 or passive immunization with a specific monoclonal antibody protects BALB/c mice against lethal Plasmodium yoelii yoelii YM blood-stage infection. Infect. Immun. 68, 2899-2906.
38. Pabst, M., Chang, M., Stadlmann, J. and Altmann, F. (2012) Glycan profiles of the 27 N-glycosylation sites of the HIV envelope protein CN54gp140. Biol. Chem. 393, 719-730.
39. Pantophlet, R., Wilson, I.A. and Burton, D.R. (2003) Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design. J. Virol. 77, 5889-5901.
40. Pantophlet, R., Wilson, I.A. and Burton, D.R. (2004) Improved design of an antigen with enhanced specificity for the broadly HIV-neutralizing antibody b12. Protein Eng. Des. Sel. 17, 749-758.
41. Pelham, H.R. (1988) Evidence that luminal ER proteins are sorted from secreted proteins in a post-ER compartment. EMBO J. 7, 913-918.
42. Pettersen, E.F., Goddard, T.D., Huang, C.C., Couch, G.S., Greenblatt, D.M., Meng, E.C. and Ferrin, T.E. (2004) UCSF Chimera-a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605-1612.
43. Pol, E., Karlsson, R., Roos, H., Jansson, A., Xu, B., Larsson, A., Jarhede, T., Franklin, G., Fuentes, A. and Persson, S. (2007) Biosensor-based characterization of serum antibodies during development of an anti-IgE immunotherapeutic against allergy and asthma. J. Mol. Recognit. 20, 22-31.
44. Polley, S.D. and Conway, D.J. (2001) Strong diversifying selection on domains of the Plasmodium falciparum apical membrane antigen 1 gene. Genetics, 158, 1505-1512.
45. Pradel, G., Hayton, K., Aravind, L., Iyer, L.M., Abrahamsen, M.S., Bonawitz, A., Mejia, C. and Templeton, T.J. (2004) A multidomain adhesion protein family expressed in Plasmodium falciparum is essential for transmission to the mosquito. J. Exp. Med. 199, 1533-1544.
46. van Ree, R., Cabanes-Macheteau, M., Akkerdaas, J., Milazzo, J.P., Loutelier-Bourhis, C., Rayon, C., Villalba, M., Koppelman, S., Aalberse, R., Rodriguez, R., Faye, L. and Lerouge, P. (2000) Beta (1, 2)-xylose and alpha (1, 3)-fucose residues have a strong contribution in IgE binding to plant glycoallergens. J. Biol. Chem, 275, 11451-11458.
47. Remarque, E.J., Faber, B.W., Kocken, C.H. and Thomas, A.W. (2008a) Apical membrane antigen 1: a malaria vaccine candidate in review. Trends Parasitol. 24, 74-84.
48. Remarque, E.J., Faber, B.W., Kocken, C.H. and Thomas, A.W. (2008b) A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits. Infect. Immun. 76, 2660-2670.
49. Roestenberg, M., Remarque, E., de Jonge, E., Hermsen, R., Blythman, H., Leroy, O., Imoukhuede, E., Jepsen, S., Ofori-Anyinam, O., Faber, B., Kocken, C.H., Arnold, M., Walraven, V., Teelen, K., Roeffen, W., de Mast, Q., Ballou, W.R., Cohen, J., Dubois, M.C., Ascarateil, S., van der Ven, A., Thomas, A. and Sauerwein, R. (2008) Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02. PLoS ONE, 3, e3960.
50. RTSS Clinical Trials Partnership, Agnandji, S.T., Lell, B., Fernandes, J.F., Abossolo, B.P., Methogo, B.G.N.O., Kabwende, A.L., Adegnika, A.A., Mordmüller, B., Issifou, S., Kremsner, P.G., Sacarlal, J., Aide, P., Lanaspa, M., Aponte, J.J., Machevo, S., Acacio, S., Bulo, H., Sigauque, B., Macete, E., Alonso, P., Abdulla, S., Salim, N., Minja, R., Mpina, M., Ahmed, S., Ali, A.M., Mtoro, A.T., Hamad, A.S., Mutani, P., Tanner, M., Tinto, H., D'Alessandro, U., Sorgho, H., Valea, I., Bihoun, B., Guiraud, I., Kabore, B., Sombie, O., Guiguemde, R.T., Ouedraogo, J.B., Hamel, M.J., Kariuki, S., Oneko, M., Odero, C., Otieno, K., Awino, N., McMorrow, M., Muturi-Kioi, V., Laserson, K.F., Slutsker, L., Otieno, W., Otieno, L., Otsyula, N., Gondi, S., Otieno, A., Owira, V., Oguk, E., Odongo, G., Woods, J.B., Ogutu, B., Njuguna, P., Chilengi, R., Akoo, P., Kerubo, C., Maingi, C., Lang, T., Olotu, A., Bejon, P., Marsh, K., Mwambingu, G., Owusu-Agyei, S., Asante, K.P., Osei-Kwakye, K., Boahen, O., Dosoo, D., Asante, I., Adjei, G., Kwara, E., Chandramohan, D., Greenwood, B., Lusingu, J., Gesase, S., Malabeja, A., Abdul, O., Mahende, C., Liheluka, E., Malle, L., Lemnge, M., Theander, T.G., Drakeley, C., Ansong, D., Agbenyega, T., Adjei, S., Boateng, H.O., Rettig, T., Bawa, J., Sylverken, J., Sambian, D., Sarfo, A., Agyekum, A., Martinson, F., Hoffman, I., Mvalo, T., Kamthunzi, P., Nkomo, R., Tembo, T., Tegha, G., Tsidya, M., Kilembe, J., Chawinga, C., Ballou, W.R., Cohen, J., Guerra, Y., Jongert, E., Lapierre, D., Leach, A., Lievens, M., Ofori-Anyinam, O., Olivier, A., Vekemans, J., Carter, T., Kaslow, D., Leboulleux, D., Loucq, C., Radford, A., Savarese, B., Schellenberg, D., Sillman, M. and Vansadia, P. (2012) A phase 3 trial of RTS, S/AS01 malaria vaccine in African infants. N. Engl. J. Med. 367, 2284-2295.
51. Rybicki, E.P. (2010) Plant-made vaccines for humans and animals. Plant Biotechnol. J. 8, 620-637.
52. Sampath, S., Carrico, C., Janes, J., Gurumoorthy, S., Gibson, C., Melcher, M., Chitnis, C.E., Wang, R., Schief, W.R. and Smith, J.D. (2013) Glycan masking of Plasmodium vivax duffy binding protein for probing protein binding function and vaccine development. PLoS Pathog. 9, e1003420.
53. Samuelson, J., Banerjee, S., Magnelli, P., Cui, J., Kelleher, D.J., Gilmore, R. and Robbins, P.W. (2005) The diversity of dolichol-linked precursors to Asn-linked glycans likely results from secondary loss of sets of glycosyltransferases. Proc. Natl Acad. Sci. USA 102, 1548-1553.
54. Schulze, I.T. (1997) Effects of glycosylation on the properties and functions of influenza virus hemagglutinin. J. Infect. Dis. 176(Suppl 1), 24-28.
55. Sriraman, R., Bardor, M., Sack, M., Vaquero, C., Faye, L., Fischer, R., Finnern, R. and Lerouge, P. (2004) Recombinant anti-hCG antibodies retained in the endoplasmic reticulum of transformed plants lack core-xylose and core-alpha (1, 3)-fucose residues. Plant Biotechnol. J. 2, 279-287.
56. Thera, M.A., Doumbo, O.K., Coulibaly, D., Diallo, D.A., Kone, A.K., Guindo, A.B., Traore, K., Dicko, A., Sagara, I., Sissoko, M.S., Diarra, I., Niangaly, A., Dolo, A., Daou, M., Diawara, S.I., Heppner, D.G., Stewart, V.A., Angov, E., Bergmann-Leitner, E.S., Lanar, D.E., Dutta, S., Soisson, L., Diggs, C.L., Leach, A., Owusu, A., Dubois, M.C., Cohen, J., Nixon, J.N., Gregson, A., Takala, S.L., Lyke, K.E. and Plowe, C.V. (2008) Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial. PLoS ONE, 3, e1465.
57. Trager, W. and Jensen, J.B. (1976) Human malaria parasites in continuous culture. Science, 193, 673-675.
58. Triguero, A., Cabrera, G., Cremata, J.A., Yuen, C.T., Wheeler, J. and Ramírez, N.I. (2005) Plant-derived mouse IgG monoclonal antibody fused to KDEL endoplasmic reticulum-retention signal is N-glycosylated homogeneously throughout the plant with mostly high-mannose-type N-glycans. Plant Biotechnol. J. 3, 449-457.
59. Voss, A., Niersbach, M., Hain, R., Hirsch, H.J., Liao, Y.C., Kreuzaler, F. and Fischer, R. (1995) Reduced virus infectivity in nicotiana tabacum secreting a TMV-specific full-size antibody. Mol. Breed. 1, 39-50.
60. Vulliez-Le Normand, B., Tonkin, M.L., Lamarque, M.H., Langer, S., Hoos, S., Roques, M., Saul, F.A., Faber, B.W., Bentley, G.A., Boulanger, M.J. and Lebrun, M. (2012) Structural and functional insights into the malaria parasite moving junction complex. PLoS Pathog. 8, e1002755.
61. Waheed, M.T., Gottschamel, J., Hassan, S.W. and Lössl, A.G. (2012) Plant-derived vaccines: an approach for affordable vaccines against cervical cancer. Hum. Vaccin. Immunother. 8, 403-406.
62. Williams, A.R., Douglas, A.D., Miura, K., Illingworth, J.J., Choudhary, P., Murungi, L.M., Furze, J.M., Diouf, A., Miotto, O., Crosnier, C., Wright, G.J., Kwiatkowski, D.P., Fairhurst, R.M., Long, C.A. and Draper, S. (2012) Enhancing blockade of Plasmodium falciparum erythrocyte invasion: assessing combinations of antibodies against PfRH5 and other merozoite antigens. PLoS Pathog. 8, e1002991.
63. World Health Organization (2012). Ld Malaria Report 2012 World Health Organization.
64. Yusibov, V., Streatfield, S.J. and Kushnir, N. (2011) Clinical development of plant-produced recombinant pharmaceuticals: vaccines, antibodies and beyond. Hum. Vaccin. 7, 313-321.